 |
|
|
|
July 1999 Cover
|
|
Initial data suggests that Interleukin 12 (IL-12) proves effective in fighting AIDS-related Kaposi's sarcoma. Subjects self-administered escalating doses of IL-12 twice
a week, utilizing a subcutaneous delivery system. The investigators found that seven of nine evaluable patients achieved a 50
percent drop in number or size of lesions and no evidence of
progression. The subjects responded within 16 weeks, on average.
The researchers, who presented their findings last week at the Third National AIDS Malignancy Conference, said the data was encouraging, because IL-12 was
very well tolerated, unlike IL-2.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
